12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Remoxy oxycodone: Phase I start

Pfizer registered on clinicaltrials.gov an open-label, 3-way crossover Phase I trial to compare 40 mg Remoxy oxycodone vs. the original oxycodone formulation in about 18 healthy volunteers. Pfizer said the study is required for Remoxy's development but does not mean the pharma has made a decision on the program.

In May, Pfizer said it had...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >